no-js

Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford, UK and benefits from excellent links with the global Ludwig Cancer Research and local Oxford research communities. Hear more about Ludwig Cancer Research and the Oxford Branch in this film made on the Branch's 10th Anniversary in Oxford:

News

Colin_286x100 160311n_0845

BRN2 reprogrammes DNA repair and promotes survival in melanoma

Posted 26/02/2019

Solar UV irradiation of the skin causes DNA damage, which if not repaired correctly, can result in mutations. Consistently, cutaneous melanoma frequently has a high mutational burden, making it more aggressive and difficult to treat. However, it is not known whether these cells have specific pro-survival mechanisms or enhanced DNA repair capacity. The transcription factor BRN2 is a known driver of invasiveness and regulator of proliferation in melanoma. In this article published in Genes and Development, Katie Herbert and colleagues from Colin Goding’s lab show that BRN2 associates with sites of DNA damage and promotes a more error-prone DNA repair mechanism. Furthermore, BRN2 also reduces cell death of damaged cells. This work has implications for the treatment of melanoma using DNA-damaging agents in cancers expressing BRN2.

Senior Group Leader in Infection, Inflammation or Cancer Epigenetics

Posted 01/03/2019

Competitive Salary

Applications are invited for two Senior Group Leaders in cancer research with expertise in infection, inflammation or epigenetics at the Ludwig Institute for Cancer Research, Oxford. We are seeking established leaders with a proven track record of scientific breakthroughs in their field. With the support of generous core funding from the Ludwig Institute and external grant funding, you will lead a substantial and effective research group that focuses on the development of a cancer research programme with a view to translating findings to benefit patients. Applications must be made online by 12.00 noon (UK time) on 12th April 2019.

Recent publications

Motion sensing superpixels (MOSES) is a systematic computational framework to quantify and discover cellular motion phenotypes. Elife, 8. Article

Bisulfite-free direct detection of 5-methylcytosine and 5-hydroxymethylcytosine at base resolution. Nat Biotechnol. Article

BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma. Genes Dev, 33 (5-6), pp. 310-332. Article

Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells. Autophagy, pp. 1-14. Article

Bisulfite-free and base-resolution analysis of 5-methylcytidine and 5-hydroxymethylcytidine in RNA with peroxotungstate. Chem Commun (Camb), 55 (16), pp. 2328-2331. Article

Research

Our researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Many of the research groups are interested the causes and consequences of differences among cells within a tumour and variability among different tumours. Find out more about the Ludwig research groups.

 

Seminars

Ludwig Seminars take place in the NDMRB (TDI) Basement Seminar Room. All University members welcome.

Dr Joanna Loizou: “Safeguarding the human genome”. , 19/Mar/2019 11:00

Browse the Ludwig Seminar Series

 

 

abstract cell culture 580x75 160311n_0736